Coeruleus Ltd. Report issue

For profit Phase 2
Founded: Katzrin Israel (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2010
NCT01071889
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

flumazenil (mazicon ) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sleep Initiation and Maintenance Disorders (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1